Johnson & Johnson bets big on America, credits Trump tax policies for investment

Key Points:

• Johnson & Johnson is committing $55 billion to U.S. investments, attributing this decision to favorable tax policies under the Trump administration, top talent, and a strong investment climate, signaling increased confidence in American manufacturing.
• CEO Joaquin Duato emphasized the company's goal to manufacture all medicines and medical technologies in the U.S., highlighting a recent $1 billion investment in a Vision manufacturing facility in Jacksonville, Florida.
• The company is focusing on science and innovation, with new products like Icotyde, an oral treatment for autoimmune diseases, and a robotic surgical system aimed at improving surgical outcomes.
• Johnson & Johnson boasts 28 product platforms generating over $1 billion each, supporting its target of achieving double-digit growth by the end of the decade despite being a $100 billion company.
• Duato differentiated the company’s current focus on pharmaceuticals and medical technology from its former consumer health segment, underscoring a strategic shift toward patient breakthroughs and sustained growth.